SPOP and prostate carcinoma: In addition, the overexpression of serine peptidase inhibitor, Kazal type 1 (SPINK1), protein, although not defining a molecular subtype, has been reported in approximately 10% of primary prostate cancer and is both mutually exclusive from ETS rearrangements and associated with SPOP mutations (17).